JP2012158540A - セラミド産生促進剤 - Google Patents
セラミド産生促進剤 Download PDFInfo
- Publication number
- JP2012158540A JP2012158540A JP2011018293A JP2011018293A JP2012158540A JP 2012158540 A JP2012158540 A JP 2012158540A JP 2011018293 A JP2011018293 A JP 2011018293A JP 2011018293 A JP2011018293 A JP 2011018293A JP 2012158540 A JP2012158540 A JP 2012158540A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- ceramide
- production
- diou
- atopic dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 52
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 title claims abstract description 50
- 229940106189 ceramide Drugs 0.000 title claims abstract description 50
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 title claims abstract description 50
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 title claims abstract description 50
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 title claims abstract description 49
- 239000000284 extract Substances 0.000 claims abstract description 52
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 14
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 14
- 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract description 12
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 208000017520 skin disease Diseases 0.000 abstract description 6
- 210000005175 epidermal keratinocyte Anatomy 0.000 abstract description 5
- 210000003491 skin Anatomy 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 235000005491 Geranium thunbergii Nutrition 0.000 abstract description 2
- 241001166194 Geranium wilfordii Species 0.000 abstract 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 229940058015 1,3-butylene glycol Drugs 0.000 description 10
- 235000019437 butane-1,3-diol Nutrition 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- -1 sorbit Chemical compound 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241001071795 Gentiana Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 241000722363 Piper Species 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000020083 shōchū Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- GKVQPWWCDQIXGN-KJEVAUFKSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-(1,2,3-trihydroxypropyl)oxane-3,4,5-triol Chemical class OCC(O)C(O)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GKVQPWWCDQIXGN-KJEVAUFKSA-N 0.000 description 1
- HOMYIYLRRDTKAA-UHFFFAOYSA-N 2-hydroxy-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]hexadecanamide Chemical compound CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=CCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O HOMYIYLRRDTKAA-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 244000250392 Cardamine diphylla Species 0.000 description 1
- 235000001250 Cardamine diphylla Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 244000105059 Geranium thunbergii Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000019860 lauric fat Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
【解決手段】ジオウ及びゲンノショウコ抽出物からなる群より選ばれる少なくとも1種の抽出物は、高いセラミド産生促進効果を有し、皮膚におけるセラミドの産生を促進することによって、扁平上皮癌、乾癬及びアトピー性皮膚炎等の皮膚疾患を治療及び予防することが可能である。
【選択図】なし
Description
抽出する溶媒としては、例えば、水、低級アルコール類(メタノール、エタノール、1−プロパノール、2−プロパノール、1−ブタノール、2−ブタノール等)、液状多価アルコール(1,3−ブチレングリコール、プロピレングリコール、グリセリン等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン、流動パラフィン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル等)が挙げられる。好ましくは、水、低級アルコール及び液状多価アルコール等の極性溶媒が良く、特に好ましくは、水、エタノール、1,3−ブチレングリコール及びプロピレングリコールが良い。これらの溶媒は1種でも2種以上を混合して用いても良い。
地黄100gに精製水2Lを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してジオウの熱水抽出物を9.2g得た。
地黄100gにエタノール2Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、ジオウのエタノール抽出物を16.8g得た。
地黄20gに精製水200mL及び1,3−ブチレングリコール200mLを加え、常温で7日間抽出した後、濾過し、ジオウの50%1,3−ブチレングリコール水溶液抽出物を360g得た。
ゲンノショウコの根及び茎の乾燥物50gに精製水1Lを加え、100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してゲンノショウコの熱水抽出物を4.6g得た。
ゲンノショウコの葉及び茎の乾燥物50gにエタノール1Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、ゲンノショウコのエタノール抽出物を8.6g得た。
ゲンノショウコの葉及び花の乾燥物20gに精製水200mL及び1,3−ブチレングリコール200mLを加え、常温で7日間抽出した後、濾過し、ゲンノショウコの50%1,3−ブチレングリコール水溶液抽出物を330g得た。
処方 配合量(g)
1.ジオウの熱水抽出物(製造例1) 0.3
2.クエン酸 0.7
3.果糖ブドウ糖液糖 60.0
4.香料 0.1
5.精製水 38.9
[製造方法]成分5に成分1〜4を加え、攪拌溶解して濾過し、加熱殺菌後、ガラス瓶に充填した。
処方 配合量(g)
1.ゲンノショウコのエタノール抽出物(製造例5) 5.0
2.トウモロコシデンプン 10.0
3.精製白糖 20.0
4.カルボキシメチルセルロースカルシウム 10.0
5.微結晶セルロース 40.0
6.ポリビニルピロリドン 5.0
7.タルク 10.0
[製造方法]成分1〜5を混合し、次いで成分6の水溶液を結合剤として加え、常法により顆粒化した。これに滑沢剤として成分7を加えて混合した後、1錠100mgの錠剤に打錠した。
処方 配合量(g)
1.ジオウのエタノール抽出物(製造例2) 2.0
2.微結晶セルロース 60.0
3.トウモロコシデンプン 18.0
4.乳糖 18.0
5.ポリビニルピロリドン 2.0
[製造方法]成分1〜5を混合して顆粒化した後、2号硬カプセルに250mg充填してカプセル剤を得た。
処方 配合量(g)
1.ゲンノショウコの熱水抽出物(製造例4) 0.1
2.スクワラン 5.5
3.オリーブ油 3.0
4.ステアリン酸 2.0
5.ミツロウ 2.0
6.ミリスチン酸オクチルドデシル 3.5
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ベヘニルアルコール 1.5
9.モノステアリン酸グリセリン 2.5
10.香料 0.1
11.1,3−ブチレングリコール 8.5
12.パラオキシ安息香酸エチル 0.05
13.パラオキシ安息香酸メチル 0.2
14.精製水 68.05
[製造方法]成分2〜9を加熱溶解して混合し、70℃に保ち油相とする。成分1及び11〜14を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、更に30℃まで冷却してクリームを得た。
処方 配合量(g)
1.ジオウの50%1,3−ブチレングリコール抽出物
(製造例3) 0.01
2.ゲンノショウコの50%1,3−ブチレングリコール抽出物
(製造例6) 0.5
3.ポリオキシエチレンセチルエーテル(30E.O.) 2.0
4.モノステアリン酸グリセリン 10.0
5.流動パラフィン 5.0
6.セタノール 6.0
7.パラオキシ安息香酸メチル 0.1
8.プロピレングリコール 10.0
9.精製水 66.39
[製造方法]成分3〜6を加熱溶解して混合し、70℃に保ち油相とした。成分1、2及び7〜9を加熱溶解して混合し、75℃に保ち水相とした。油相に水相を加えて乳化して、かき混ぜながら30℃まで冷却して軟膏を得た。
ヒト表皮ケラチノサイト由来細胞株であるHaCaT細胞を60mmディッシュに1×105個播種し、4日間培養した。その後、試料を最終濃度が1、10及び100μg/mLになるように添加し、更に24時間培養した。次に、細胞をPBS(−)にて3回洗浄した後、ラバーポリスマンにて集め、凍結乾燥させた。クロロホルム:メタノール(2:1)1mLにて細胞から脂質を抽出し、その中のセラミド量をKisic等の蛍光法(Kisic A. and Rapport M.M., Journal of Lipid Research, 15 179−180 (1974))により測定した。即ち、脂質を3N塩酸0.15mLにて100℃で2時間加水分解し、デシケーター中で乾燥、塩酸除去した後、酢酸エチル2mLと0.1N酢酸緩衝液(pH3.7)1.25mLを加え、よく攪拌した。次に、フルオレスカミン溶液(フルオレスカミン 7mg/25mL アセトン)0.25mLを加え、よく攪拌した後、遠心分離し、酢酸エチル層の蛍光強度をEx410nm、Em490nmにて測定した。以下の式により、セラミド産生促進率を求めた。
セラミド産生促進率(%)=(試料添加した場合のセラミド産生量/コントロールのセラミド産生量)×100
Claims (4)
- ジオウ及びゲンノショウコ抽出物からなる群より選ばれる少なくとも1種の抽出物を含有するセラミド産生促進剤。
- ジオウ及びゲンノショウコ抽出物からなる群より選ばれる少なくとも1種の抽出物を含有する扁平上皮癌の治療薬。
- ジオウ及びゲンノショウコ抽出物からなる群より選ばれる少なくとも1種の抽出物を含有する乾癬の治療薬。
- ジオウ及びゲンノショウコ抽出物からなる群より選ばれる少なくとも1種の抽出物を含有するアトピー性皮膚炎の治療薬。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011018293A JP5649995B2 (ja) | 2011-01-31 | 2011-01-31 | セラミド産生促進剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011018293A JP5649995B2 (ja) | 2011-01-31 | 2011-01-31 | セラミド産生促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012158540A true JP2012158540A (ja) | 2012-08-23 |
JP5649995B2 JP5649995B2 (ja) | 2015-01-07 |
Family
ID=46839383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011018293A Active JP5649995B2 (ja) | 2011-01-31 | 2011-01-31 | セラミド産生促進剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5649995B2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210064460A (ko) * | 2019-11-25 | 2021-06-03 | 대한민국(농촌진흥청장) | 노랑느타리 및 지황 복합 추출물을 유효성분으로 포함하는 피부질환 예방 및 치료용 조성물 |
JP7040833B1 (ja) * | 2021-05-18 | 2022-03-23 | 株式会社アイビー化粧品 | Jak阻害剤 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000136144A (ja) * | 1998-11-02 | 2000-05-16 | Shiseido Co Ltd | 抗プラスミン剤 |
JP2000169383A (ja) * | 1998-12-07 | 2000-06-20 | Ichimaru Pharcos Co Ltd | 抗アレルギー剤 |
WO2000059517A1 (en) * | 1999-04-07 | 2000-10-12 | Roger Williams Hospital | Ceramide and chemotherapeutic agents for inducing cell death |
JP2001261543A (ja) * | 2000-03-17 | 2001-09-26 | Kao Corp | 皮膚化粧料 |
JP2003012495A (ja) * | 2001-07-06 | 2003-01-15 | Kanebo Ltd | 化粧料 |
JP2003104886A (ja) * | 2001-09-28 | 2003-04-09 | Lion Corp | 皮膚外用剤組成物 |
JP2010001264A (ja) * | 2008-06-23 | 2010-01-07 | Taisho Pharmaceutical Co Ltd | 神経伸長抑制剤 |
WO2010020165A1 (zh) * | 2008-08-18 | 2010-02-25 | 复旦大学附属中山医院 | 神经酰胺产生促进剂 |
-
2011
- 2011-01-31 JP JP2011018293A patent/JP5649995B2/ja active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000136144A (ja) * | 1998-11-02 | 2000-05-16 | Shiseido Co Ltd | 抗プラスミン剤 |
JP2000169383A (ja) * | 1998-12-07 | 2000-06-20 | Ichimaru Pharcos Co Ltd | 抗アレルギー剤 |
WO2000059517A1 (en) * | 1999-04-07 | 2000-10-12 | Roger Williams Hospital | Ceramide and chemotherapeutic agents for inducing cell death |
JP2001261543A (ja) * | 2000-03-17 | 2001-09-26 | Kao Corp | 皮膚化粧料 |
JP2003012495A (ja) * | 2001-07-06 | 2003-01-15 | Kanebo Ltd | 化粧料 |
JP2003104886A (ja) * | 2001-09-28 | 2003-04-09 | Lion Corp | 皮膚外用剤組成物 |
JP2010001264A (ja) * | 2008-06-23 | 2010-01-07 | Taisho Pharmaceutical Co Ltd | 神経伸長抑制剤 |
WO2010020165A1 (zh) * | 2008-08-18 | 2010-02-25 | 复旦大学附属中山医院 | 神经酰胺产生促进剂 |
Non-Patent Citations (1)
Title |
---|
JPN6014038292; Mutation Research Vol.523-524, 2003, p.119-125 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210064460A (ko) * | 2019-11-25 | 2021-06-03 | 대한민국(농촌진흥청장) | 노랑느타리 및 지황 복합 추출물을 유효성분으로 포함하는 피부질환 예방 및 치료용 조성물 |
KR102379555B1 (ko) * | 2019-11-25 | 2022-03-30 | 대한민국 | 노랑느타리 및 지황 복합 추출물을 유효성분으로 포함하는 피부질환 예방 및 치료용 조성물 |
JP7040833B1 (ja) * | 2021-05-18 | 2022-03-23 | 株式会社アイビー化粧品 | Jak阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
JP5649995B2 (ja) | 2015-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6411580B2 (ja) | 三白草抽出物を含有する皮脂生成抑制用組成物 | |
JP2006111560A (ja) | セラミド合成促進剤 | |
EP1859834B1 (en) | Anti-inflammatory agent | |
KR102459649B1 (ko) | 신규한 흰무늬엉겅퀴 수과 추출물 및 피부과 및 피부 화장료에서 이의 용도 | |
JP2006124350A (ja) | Nmf産生促進剤 | |
JP2711630B2 (ja) | 皮膚外用剤 | |
JP2008255051A (ja) | セラミド合成促進剤、皮膚バリア機能改善剤及びセラミド合成障害に起因する疾患の予防・治療剤 | |
JP5649995B2 (ja) | セラミド産生促進剤 | |
JP4980035B2 (ja) | 皮膚外用剤、美白剤及び内用組成物 | |
CN116889529A (zh) | 一种包括灵芝提取物的用于改善头发或头皮状态的组合物 | |
JP5154835B2 (ja) | 美白化粧料 | |
JP2012020964A (ja) | グルタチオン産生促進剤及びグルタチオン産生促進作用を有する医薬品、食品又は化粧料 | |
JP4579550B2 (ja) | セラミド合成促進剤及び皮膚外用剤 | |
KR101700850B1 (ko) | 소맥엽 추출물을 유효성분으로 포함하는 과민면역반응 질환의 예방, 개선 또는 치료용 조성물 | |
KR102144566B1 (ko) | 택란 추출물을 유효성분으로 포함하는 아토피 피부염의 예방 또는 치료용 조성물 | |
JP2017178862A (ja) | 抗炎症剤、化粧料、皮膚外用剤、炎症性疾患の改善剤、及び抗炎症剤の製造方法 | |
JP2011088854A (ja) | インボルクリン発現抑制剤 | |
KR102675988B1 (ko) | 3,3',4-tri-O-methylellagic acid를 유효성분으로 포함하는 피부 개선용 조성물 | |
JP6688585B2 (ja) | バリア機能改善剤 | |
JP6281761B2 (ja) | ヒダカミセバヤエキスを含有する外用剤又は内用剤 | |
JP4402278B2 (ja) | 美白化粧料 | |
KR102073009B1 (ko) | 병풀 피토솜 및 상백피 추출물을 유효성분으로 포함하는 피부 염증 예방 또는 치료용 조성물 | |
JP5992661B2 (ja) | ヒアルロン酸産生促進剤 | |
JP5690149B2 (ja) | 外用剤又は内用剤 | |
JP3852262B2 (ja) | セラミド合成促進剤、皮膚化粧料及び入浴剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141003 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141111 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141112 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5649995 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |